NASDAQ: TLSA - Tiziana Life Sciences Ltd

六个月盈利: -21.65%
部门: Healthcare

促销时间表 Tiziana Life Sciences Ltd

先进的时间表 简单图表
Financial Markets by TradingView

关于公司

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

更多详情
It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2000-03-24
ISIN BMG889121031
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.tizianalifesciences.com
Цена ао 0.426
每日价格变化: -3.8% (0.6996)
每周价格变化: -13.16% (0.775)
每月价格变化: -26.85% (0.92)
3个月内价格变化: -33.37% (1.01)
六个月内的价格变化: -21.65% (0.859)
每年价格变化: +20.18% (0.56)
3年内价格变化: -30.62% (0.97)
5年内价格变化: -75.75% (2.7751)
10年价格变化: +0% (0.673)
年初以来价格变化: -34.02% (1.02)
所有参数

低估

姓名 意义 年级
P/S 0 0
P/BV 2.91 6
P/E 0 0
EV/EBITDA -2.55 0
全部的: 3.25

效率

姓名 意义 年级
ROA, % -145.2 0
ROE, % -319.56 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0161 10
全部的: 10

成长冲动

姓名 意义 年级
盈利能力 Revenue, % -97.64 0
盈利能力 Ebitda, % 29.82 4
盈利能力 EPS, % 1356.45 10
全部的: 5.4
更多详情

机构 体积 分享, %
Geode Capital Management, LLC 211167 0.21
HSBC Holdings PLC 164226 0.16
Morgan Stanley 124131 0.12
Ausdal Financial Partners, Inc. 55700 0.05
Zhang Financial LLC 52060 0.05
Ewa, LLC 43476 0.04
UBS Group AG 28559 0.03
Bank of America Corporation 27011 0.03
Barclays PLC 17500 0.02
Cubist Systematic Strategies, LLC 12099 0.01



导师 职称 支付 出生年份
Mr. Gabriele Marco Antonio Cerrone M.B.A. Founder, Executive Chairman & Interim CEO 817k 1972 (53 年)
Ms. Keeren Shah Chief Financial Officer 1976 (49 年)
Dr. William A. Clementi Ph.D., Pharm.D. Chief Development Officer
Dr. Napoleone Ferrara M.D. Member of Scientific Advisory Board 1957 (68 年)

地址: United Kingdom, London WS XJ, 14/15 Conduit Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.tizianalifesciences.com